Reaching the Final Endgame for Constant Waves of COVID-19

Viruses, Journal Year: 2022, Volume and Issue: 14(12), P. 2637 - 2637

Published: Nov. 25, 2022

Despite intramuscular vaccines saving millions of lives, constant devastating waves SARS-CoV-2 infections continue. The elimination COVID-19 is challenging, but necessary in order to avoid more people who would suffer from long COVID if we fail. Our paper describes rapidly advancing and innovative therapeutic strategies for the early stage infection with so that tolerating continuing cycles should be unnecessary future. These therapies include new broader specificities, nasal antiviral drugs some targeting at first preventing virus entering body place. article advantages disadvantages each these options which various combinations could eventually prevent renewed infection. Finally, important consideration given political, social economic barriers since 2020 hindered vaccine application are likely interfere again any endgame.

Language: Английский

---

Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment

Therapeutic Advances in Respiratory Disease, Journal Year: 2022, Volume and Issue: 16

Published: Jan. 1, 2022

On 30 January 2020, the World Health Organization (WHO) declared novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic a public health emergency of international concern. The viral outbreak led in turn to an exponential growth disease 2019 (COVID-19) cases, that is, multiorgan has more than 6.3 million deaths worldwide, as June 2022. There are currently few effective drugs approved for treatment SARS-CoV-2/COVID-19 patients. Many compounds tested so far have been selected through drug repurposing approach, by identifying indications already other conditions. We here present up-to-date review main Food and Drug Administration (FDA)-approved repurposed against SARS-CoV-2 infection, discussing their mechanism action most important preclinical clinical results. Reviewed were chosen privilege those use patients or completed phase III trials. Moreover, we also summarize evidence on some promising pipeline. Finally, discuss current stage possible steps toward development broadly combinations suppress onset progression COVID-19.

Language: Английский

---

Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises

Biophysical Chemistry, Journal Year: 2022, Volume and Issue: 290, P. 106891 - 106891

Published: Sept. 11, 2022

Language: Английский

---

Cost-effectiveness analysis of COVID-19 treatment for hospitalized patients: a healthcare provider perspective in Batam, Indonesia

Journal of Public Health and Development, Journal Year: 2023, Volume and Issue: 21(2), P. 282 - 294

Published: May 26, 2023

The COVID-19 pandemic is a global crisis that has continued to impact health, population, and the economy. Therefore, this study aims evaluate cost-effectiveness of treatment for hospitalized patients from perspective healthcare providers. An observational was conducted retrospectively by collecting data medical records between April 1 June 30, 2021. effectiveness therapy evaluated based on guidelines in Indonesia, calculating number recovered within 14 days. only considered direct costs treatment, while analyzed using Average Cost-Effectiveness Ratio (ACER) Incremental (ICER). results showed average cost per patient approximately IDR 28,114,775.52 ± 16,352,597.11. most effective Favipiravir + Levofloxacin N-acetylcysteine, followed Azithromycin with 97% 91% effectiveness, respectively. ACER treatments ranged Rp 15,596,973 58,140,864, ICER mainly located South East Quadrant, N-acetylcysteine being dominant compared other treatments, saving 161,653.97 33,870,916.17 patient. Effective provide good value health system. However, limited unavailability recent information rapidly evolving pandemic.

Language: Английский

---

Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(20), P. 15471 - 15471

Published: Oct. 23, 2023

COVID-19 pandemic has caused widespread panic and fear among the global population. As such, repurposing drugs are being used as viable therapeutic options due to limited effective treatments for Long COVID symptoms. Ivermectin is one of emerging repurposed that been shown have antiviral effects in clinical trials. In addition, antioxidant compounds also gaining attention their capabilities reducing inflammation severity Due absence knowledge pharmacogenomics modes actions human body these compounds, this study aims provide a pharmacogenomic profile combination ivermectin six selected antioxidants (epigallocatechin gallate (EGCG), curcumin, sesamin, anthocyanins, quercetin, N-acetylcysteine (NAC)) potentially regimens long Results showed there were 12 interacting genes found ivermectin, 6 antioxidants, COVID-19. For network pharmacology, common genes/proteins had highest associations with Pertussis pathway, AGE-RAGE signaling pathway diabetic complications, colorectal cancer Kyoto Encyclopedia Genes Genomes (KEGG) analyses. Disease analyses revealed top three relevant diseases infections diabetes mellitus, ischemia, reperfusion injury. We identified potential target microRNAs (miRNAs) commonly curated molecular biomarkers treatments. The established network, disease analyses, miRNAs could facilitate developments chronic sequelae especially post-pandemic era. However, further studies trials needed substantiate effectiveness dosages

Language: Английский

---